ReviewNature reviews. Urology2025
Optimizing cystoscopy and TURBT: enhanced imaging and artificial intelligence.
Review in Nature reviews. Urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- The Stalk Sign in Bladder Cancer: CEUS Versus MRI.Diagnostics (Basel, Switzerland) · 2026Article
- Application of transformer-enhanced convolutional neural network: multicenter MRI assessment of muscle invasion in bladder cancer.European radiology · 2026Article
- A multi-modal approach for decision making in bladder cancer.Nature reviews. Urology · 2026Review
- Artificial intelligence and predictive tools in non-muscle invasive bladder cancer: a narrative review of current insights and advances.Translational andrology and urology · 2026Review
- Nanosensor-coated catheters for bladder cancer detection.Nature nanotechnology · 2026Article
- Chemical efflux imaging using an annular nanosensor array for in situ bladder cancer detection.Nature nanotechnology · 2026Article
- Enhanced detection of bladder cancer using combined circulating tumor cells, urine-derived epithelial cells, and molecular biomarkers.Journal of cancer research and clinical oncology · 2026Article
- Article
- Advances in the management of localized bladder cancers.Nature reviews. Clinical oncology · 2026Review
- CystoDS: a multiclass endoscopy image dataset for artificial intelligence-assisted bladder cancer detection.Scientific data · 2026Article
- Artificial intelligence-assisted diagnosis and histopathological grading of bladder cancer: current status, challenges, and future directions.Frontiers in digital health · 2026Review
- Applications of AI in urology.Nature reviews. Urology · 2026Article
- Beyond Visualization: Advanced Imaging, Theragnostics and Biomarker Integration in Urothelial Bladder Cancer.Cancers · 2025Review
- A novel artificial intelligence segmentation model for early diagnosis of bladder tumors.Abdominal radiology (New York) · 2025Article
- Advancing Bladder Health Diagnostics: The Potential of Optical Techniques for Noninvasive Assessment of Lower Urinary Tract Disorders.International neurourology journal · 2025Article
- Integrating multi-omics data reveals the antitumor role and clinical benefits of gamma-delta T cells in triple-negative breast cancer.BMC cancer · 2025Article
- Perspective on the use of optics in bladder cancer detection and diagnosis.Journal of biomedical optics · 2025Review
- Artificial intelligence for diagnosing bladder pathophysiology: An updated review and future prospects.Bladder (San Francisco, Calif.) · 2025Review
- Low-cost and label-free blue light cystoscopy through digital staining of white light cystoscopy videos.Communications medicine · 2024Article
- Nature Reviews Urology: evolving with the field for 20 years.Nature reviews. Urology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Diagnostic cystoscopy in combination with transurethral resection of the bladder tumour are the standard for the diagnosis, surgical treatment and surveillance of bladder cancer. The ability to inspect the bladder in its current form stems from a long chain of advances in imaging science and endoscopy. Despite these advances, bladder cancer recurrence and progression rates remain high after endoscopic resection. This stagnation is a result of the heterogeneity of cancer biology as well as limitations in surgical techniques and tools, as incomplete resection and provider-specific differences affect cancer persistence and early recurrence. An unmet clinical need remains for solutions that can improve tumour delineation and resection. Translational advances in enhanced cystoscopy technologies and artificial intelligence offer promising avenues to overcoming the progress plateau.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.